Origimm strives to become a market leader in vaccine discovery, supplying its candidates to industry pipelines. The first product for licencing out is a vaccine antigen against acne vulgaris.
Using its proprietary ProVaDis® technology platform, Origimm strives to bring innovation in the vaccine discovery and establish themselves as a prime research oriented biotech company supplying pipelines of pharmaceutical companies, as well as developing ist own products (the first product is an antigen candidate for a therapeutic vaccine against acne vulgaris).
At Origimm, we strongly believe that best quality, most protective vaccine antigens represent the essence or the ‘origins of immunity’ (hence the name, Origimm). Our mission is dedication and purity in science for saving and improving people’s lives, under the highest ethical standards.
Origimm was founded in 2012 by Dr. Sanja Selak – the former Head of Department of Serology and Immune Assays at Intercell.
+43 676 4484825